AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
- EligibilityCriteria: Inclusion Criteria:  Adult patients (age> 18 years) treated with myeloablative or non-myeloablative HSCT 6 month prior and in outpatient follow-up without recurrent disease are eligible for inclusion.  Exclusion Criteria:  Patients with recurrence or subsequent malignancy requiring cancer treatment or lack of access to email and the Internet will be excluded. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult